Among 89 Japanese patients with tumor PD-L1 ≥ 1%, median (95% CI) OS was 58.3 (15.2–not reached [NR]) months with nivolumab plus ipilimumab versus 28.9 (23.7–54.6) months with chemotherapy (HR 0.72; 95% CI, 0.42–1.26); 5-year OS (95% CI) rate was 46% (30%–60%) versus 34% (21%–47%) (Fig. 1A). The gene discussed is CD274; the disease is neoplasm.